Found: 32
Select item for more details and to access through your institution.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Successful treatment of Evans syndrome with Tacrolimus.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 254, doi. 10.1007/s10637-014-0155-9
- By:
- Publication type:
- Article
Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 32, doi. 10.1007/s10637-014-0168-4
- By:
- Publication type:
- Article
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 109, doi. 10.1007/s10637-014-0157-7
- By:
- Publication type:
- Article
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 148, doi. 10.1007/s10637-014-0160-z
- By:
- Publication type:
- Article
Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 119, doi. 10.1007/s10637-014-0161-y
- By:
- Publication type:
- Article
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 1, doi. 10.1007/s10637-014-0156-8
- By:
- Publication type:
- Article
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 128, doi. 10.1007/s10637-014-0164-8
- By:
- Publication type:
- Article
Acetylamine derivative of diospyrin, a plant-derived binaphthylquinonoid, inhibits human colon cancer growth in Nod-Scid mice.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 22, doi. 10.1007/s10637-014-0165-7
- By:
- Publication type:
- Article
Novel benzoxazines as inhibitors of angiogenesis.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 45, doi. 10.1007/s10637-014-0172-8
- By:
- Publication type:
- Article
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 159, doi. 10.1007/s10637-014-0167-5
- By:
- Publication type:
- Article
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 12, doi. 10.1007/s10637-014-0163-9
- By:
- Publication type:
- Article
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 241, doi. 10.1007/s10637-014-0169-3
- By:
- Publication type:
- Article
Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 194, doi. 10.1007/s10637-014-0170-x
- By:
- Publication type:
- Article
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 169, doi. 10.1007/s10637-014-0166-6
- By:
- Publication type:
- Article
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 177, doi. 10.1007/s10637-014-0173-7
- By:
- Publication type:
- Article
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 257, doi. 10.1007/s10637-014-0178-2
- By:
- Publication type:
- Article
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 215, doi. 10.1007/s10637-014-0176-4
- By:
- Publication type:
- Article
Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 53, doi. 10.1007/s10637-014-0175-5
- By:
- Publication type:
- Article
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 187, doi. 10.1007/s10637-014-0177-3
- By:
- Publication type:
- Article
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 225, doi. 10.1007/s10637-014-0174-6
- By:
- Publication type:
- Article
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 201, doi. 10.1007/s10637-014-0179-1
- By:
- Publication type:
- Article
Pharmacokinetics and excretion of C-lenvatinib in patients with advanced solid tumors or lymphomas.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 233, doi. 10.1007/s10637-014-0181-7
- By:
- Publication type:
- Article
Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 64, doi. 10.1007/s10637-014-0182-6
- By:
- Publication type:
- Article
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 138, doi. 10.1007/s10637-014-0142-1
- By:
- Publication type:
- Article
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 247, doi. 10.1007/s10637-014-0186-2
- By:
- Publication type:
- Article
In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 95, doi. 10.1007/s10637-014-0187-1
- By:
- Publication type:
- Article
4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 104, doi. 10.1007/s10637-014-0188-0
- By:
- Publication type:
- Article
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 75, doi. 10.1007/s10637-014-0184-4
- By:
- Publication type:
- Article
The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 86, doi. 10.1007/s10637-014-0185-3
- By:
- Publication type:
- Article